Beta Bionics, Inc. (NASDAQ:BBNX) Short Interest Update

Beta Bionics, Inc. (NASDAQ:BBNX) was the target of a significant increase in short interest in December. As of December 31st, there was short interest totaling 7,301,052 shares, an increase of 81.6% from the December 15th total of 4,020,336 shares. Based on an average daily trading volume, of 1,075,359 shares, the days-to-cover ratio is currently 6.8 days. Approximately 16.6% of the company’s stock are sold short. Approximately 16.6% of the company’s stock are sold short. Based on an average daily trading volume, of 1,075,359 shares, the days-to-cover ratio is currently 6.8 days.

Beta Bionics Stock Down 1.6%

NASDAQ:BBNX opened at $16.99 on Thursday. The company has a market capitalization of $748.07 million and a PE ratio of -3.89. Beta Bionics has a 52-week low of $8.89 and a 52-week high of $32.71. The stock’s 50 day moving average price is $28.68 and its 200 day moving average price is $22.37.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Tuesday, October 28th. The company reported ($0.33) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The company had revenue of $27.25 million during the quarter, compared to analysts’ expectations of $23.92 million. Beta Bionics had a negative return on equity of 35.72% and a negative net margin of 87.89%.

Wall Street Analyst Weigh In

Several equities analysts recently commented on BBNX shares. Bank of America lowered Beta Bionics from a “buy” rating to a “neutral” rating in a report on Friday, January 9th. Stifel Nicolaus reissued a “buy” rating and set a $31.00 target price (up previously from $26.00) on shares of Beta Bionics in a research report on Wednesday, October 29th. Wall Street Zen cut Beta Bionics from a “hold” rating to a “sell” rating in a research note on Saturday, January 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research note on Monday, December 29th. Finally, Lake Street Capital raised their price objective on shares of Beta Bionics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Beta Bionics currently has a consensus rating of “Moderate Buy” and a consensus price target of $30.20.

Insider Activity

In related news, Director Adam Lezack sold 1,406 shares of the company’s stock in a transaction that occurred on Friday, October 31st. The shares were sold at an average price of $26.87, for a total transaction of $37,779.22. Following the sale, the director directly owned 9,841 shares in the company, valued at approximately $264,427.67. This represents a 12.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Maria Palasis sold 1,406 shares of Beta Bionics stock in a transaction that occurred on Friday, October 31st. The stock was sold at an average price of $26.91, for a total transaction of $37,835.46. Following the completion of the transaction, the director owned 9,841 shares of the company’s stock, valued at $264,821.31. This represents a 12.50% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 35,302 shares of company stock valued at $1,036,449 over the last three months.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. Divisadero Street Capital Management LP purchased a new stake in Beta Bionics during the 2nd quarter valued at approximately $13,817,000. Goldman Sachs Group Inc. purchased a new position in shares of Beta Bionics in the 1st quarter valued at approximately $715,000. Palumbo Wealth Management LLC acquired a new position in shares of Beta Bionics in the second quarter valued at approximately $431,000. Sands Capital Alternatives LLC raised its stake in shares of Beta Bionics by 15.0% during the second quarter. Sands Capital Alternatives LLC now owns 3,570,113 shares of the company’s stock worth $51,981,000 after purchasing an additional 466,331 shares during the last quarter. Finally, Walleye Capital LLC raised its stake in shares of Beta Bionics by 47.3% during the second quarter. Walleye Capital LLC now owns 218,189 shares of the company’s stock worth $3,177,000 after purchasing an additional 70,084 shares during the last quarter.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.